CFDE Data Portal | Search GREM1-AS1

	Label	Description
	GREM1-AS1 Gene (Entity type)	ENSG00000259721 - GREM1 antisense RNA 1
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 0 V 3 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 1 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE130401 4 V 3 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE67266 7 V 3 ETOPOSIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE193541 nifurtimox A-549 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

GREM1-AS1

ENSG00000259721 - GREM1 antisense RNA 1

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE197555 0 V 3 TRAMETINIB HUMAN UP

A Gene Set from LINCS

GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up

A Gene Set from LINCS

GSE108464 AZ-628 1 v 15 human up

A Gene Set from LINCS

GSE130401 4 V 3 TRAMETINIB HUMAN DN

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 5 human dn

A Gene Set from LINCS

GSE67266 7 V 3 ETOPOSIDE MOUSE UP

A Gene Set from LINCS

GSE193541 nifurtimox A-549 1 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.